Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

CELLTRION, INC. (068270)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( KRW)
Sales 2017 940 B
EBIT 2017 476 B
Net income 2017 374 B
Debt 2017 201 B
Yield 2017 0,00%
Sales 2018 1 274 B
EBIT 2018 666 B
Net income 2018 526 B
Debt 2018 16,7 B
Yield 2018 0,00%
P/E ratio 2017 73,95
P/E ratio 2018 54,08
EV / Sales2017 28,8x
EV / Sales2018 21,1x
Capitalization 26 857 B
More Financials
Company
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
11/07 CELLTRION : Healthcare presents positive results for Truxima
10/05 CELLTRION : taps Oracle Health Sciences Safety Solutions to Help Bring Cost-Effe..
09/28 CELLTRION : Taps Oracle Health Sciences Safety Solutions to Help Bring Cost-Effe..
09/25 CELLTRION : Market poles apart over Celltrion's KOSPI relocation
09/14 Roche faces prospect of second Rituxan biosimilar in US
09/06 CELLTRION : 82% of Celltrions Sales Revenues Come from Internal Dealings
08/10 CELLTRION : and Teva Announce U.S. FDA Acceptance of Biologics License Applicati..
08/02 CELLTRION : FDA accepts Celltrions BLA for breast cancer biosimilar
08/01 TEVA PHARMACEUTICAL INDUSTRIES LTD : . - Celltrion and Teva Announce U.S. FDA Ac..
07/19 Poor test results for Roche cloud growth prospects
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 172 413  KRW
Spread / Average Target -21%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Joseph Lee Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.24 494
INCYTE CORPORATION4.96%22 471
IQVIA HOLDINGS INC36.54%22 070
LONZA GROUP56.09%19 543
ALNYLAM PHARMACEUTICALS, INC.236.40%12 427
SEATTLE GENETICS, INC.9.15%8 534